Factors Associated with Preference for Long-Acting Injectable versus Daily Oral Antiretroviral Therapy among People with HIV: Findings from the SELIGO Study

Authors

Kerrigan D, Department of Prevention and Community Health, George Washington University Milken Institute School of Public Health, Washington DC, USA.
Ruiz C, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA.
Castonguay B, Department of Prevention and Community Health, George Washington University Milken Institute School of Public Health, Washington DC, USA.
Rodriguez Gonzalez H, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA.
Mayer Kh, Fenway Health, Boston, MA USA.
Fleming J, Fenway Health, Boston, MA USA.
Peretti M, Fenway Health, Boston, MA USA.
Cachay E, Department of Infectious Diseases, Mayo Clinic, Scottsdale, AZ USA.
Bamford L, University of California at San Diego, San Diego, CA USA.
Agans R, Department of Biostatistics, Gillings Global School of Public Health, University of North Carolina, Chapel Hill, NC USA.
Barrington C, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA.
Cole S, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA.
Wohl D, Department of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC USA.

Document Type

Journal Article

Publication Date

10-22-2025

Journal

Journal of acquired immune deficiency syndromes (1999)

DOI

10.1097/QAI.0000000000003781

Abstract

BACKGROUND: HIV outcomes in people with HIV (PWH) are suboptimal and inequitably distributed in the United States (US). Long-acting injectable antiretroviral therapy (LAI-ART) has potential to make important contributions to improving HIV outcomes and quality of life for PWH. METHODS: The SELIGO Study employed a one-time, 20-minute survey of 801 PWH from the Center for AIDS Research Network of Integrated Clinical Systems cohort in 3 US cities (Boston, MA; Chapel Hill, NC; San Diego, CA) which included 54 items. Using multinomial and binary logistic regression, we assessed factors associated with LAI-ART versus daily oral ART preferences. RESULTS: Most participants were cisgender men (82.3%); 57.0% identified as racial and/or ethnic minorities; mean years of age, 52.2; mean years living with HIV, 18.1; 2.8% were using LAI-ART. Compared to daily oral ART, 56.9% preferred LAI-ART administered monthly, and 68.0% preferred LAI-ART administered every 2 months. Factors associated with greater odds of LAI-ART preference included: medication/contraception injection experience, pill burden, no medication other than ART, 4 or > clinic visits per year, detectable viral load, reporting a higher number of HIV treatment considerations, and identifying as Black. Factors associated with decreased odds of LAI-ART preference included older age, identifying as neither gay nor straight, living > 1 hour from the clinic, and considerable/extreme needle fear. CONCLUSIONS: Findings demonstrate that while there is considerable interest in LAI-ART, HIV treatment modality preferences are multifaceted. Shared decision-making can ensure that conversations about ART options consistently address specific factors across diverse groups to facilitate equitable LAI-ART uptake.

APA Citation

D, Kerrigan; C, Ruiz; B, Castonguay; H, Rodriguez Gonzalez; Kh, Mayer; J, Fleming; M, Peretti; E, Cachay; L, Bamford; R, Agans; C, Barrington; S, Cole; and D, Wohl, "Factors Associated with Preference for Long-Acting Injectable versus Daily Oral Antiretroviral Therapy among People with HIV: Findings from the SELIGO Study" (2025). GW Authored Works. Paper 8243.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8243

Department

Prevention and Community Health